The short answer
On 30 April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List. If finalised, that closes the last legal pathway for most large-scale compounded GLP-1s. It followed 30 warning letters to telehealth companies in March 2026.
Key facts
- Proposal date
- 30 April 2026
- Compounds named
- Semaglutide, tirzepatide, liraglutide
- Mechanism
- Removal from the 503B Bulks List
- Warning letters
- 30 to telehealth companies, March 2026
- Comment period
- Closed end of June 2026
- Trigger
- Shortage declared over, 21 February 2025
- Jurisdiction
- United States, not the UK
Why compounding was legal in the first place
US compounding law permits pharmacies to prepare a version of a commercially available drug in defined circumstances, one of which is a declared shortage. When demand for semaglutide and tirzepatide outran supply, that exemption opened, and a large compounding industry grew inside it, much of it distributing through telehealth platforms rather than traditional pharmacy.
What changed
The FDA declared the semaglutide shortage over on 21 February 2025, which removed the main legal basis for compounding it. Enforcement escalated through 2026: 30 warning letters went to telehealth companies in March, and on 30 April the agency proposed removing semaglutide, tirzepatide and liraglutide from the 503B Bulk Drug Substances List (the list of ingredients large outsourcing facilities are permitted to use). A comment period ran to the end of June 2026.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The safety record behind it
The FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide as of early 2025. A substantial share involved dosing errors, several requiring hospitalisation, arising from patients drawing doses themselves from multi-dose vials rather than using a metered pen. That is a failure mode created by the presentation rather than by the molecule.
Why this is not a UK story, and why it matters here anyway
The 503B Bulks List is a US regulatory instrument with no UK equivalent, and the MHRA operates a different framework. But the underlying pattern is the same one the MHRA acted on when it opened investigations into UK retailers making therapeutic claims about peptides in April 2026: demand for incretin compounds outrunning licensed supply, and a grey market forming in the gap.
The distinction that matters most
Compounded GLP-1, licensed GLP-1 and research material are three different things and should never be conflated. A compounded preparation is made by a pharmacy for administration to a person. A licensed product has a marketing authorisation. Material supplied for laboratory research is neither: it is not a medicine, not a compounded preparation, not an alternative to either, and not supplied for human use. Nothing in this regulatory story creates a route from one category to another.
What happens next
Finalising the proposal could take months, and the outcome was not settled at the time of writing. If it is finalised, the practical effect is that mass compounding of these three compounds ends in the United States, leaving licensed products and clinical trials as the routes to them.
Frequently asked questions
Does this affect the UK?
Not directly. The 503B Bulks List is a US instrument. The MHRA operates a separate framework, though it has taken its own enforcement action in this area.
Why were compounded versions available at all?
US law permits compounding of a commercially available drug during a declared shortage. The semaglutide shortage was declared over in February 2025, removing that basis.
Is research material a form of compounded GLP-1?
No. Compounded preparations are made by pharmacies for administration to people. Research material is supplied for laboratory use only and is not an alternative to any medicine.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- MHRA Drug Safety Update: Semaglutide and NAIONOn 5 February 2026 the MHRA warned of a likely association between semaglutide and NAION, a rare optic neuropathy, estimated at up to 1 in 10,000 users.
- Target Trial Emulation: Making Observational Data BehaveA method for analysing routine health records as though a trial had been designed. Why it exists, what it fixes, and what it cannot fix.
- What the Cardiovascular and Kidney Data Actually IsA 2025 target trial emulation examined GLP-1 outcomes in adults with obesity. What that design can support, and how it differs from a randomised trial.
- Tirzepatide in Heart Failure With Preserved Ejection FractionA target trial emulation in Nature Communications examined tirzepatide in HFpEF. Why this population is studied and what the design supports.
- The Correction Nobody ReadsThe aleniglipron Phase 2b carries a publisher correction. So does the survodutide comparison. Checking for one is a step almost everyone skips.